nisoldipine has been researched along with Diabetes Mellitus, Type 1 in 6 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) versus an ACE inhibitor (lisinopril) on albuminuria, arterial blood pressure, and glomerular filtration rate (GFR) in hypertensive IDDM patients with diabetic nephropathy." | 9.08 | Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. ( Boelskifte, S; Jensen, BR; Nielsen, FS; Parving, HH; Rossing, P; Tarnow, L, 1997) |
| "73 m](-2); mean 24-h ambulatory blood pressure was 108 +/- 3 and 105 +/- 2 mmHg, and albuminuria was 1,554 mg/24 h (95% CI 980-2,465) and 1,033 mg/24 h (760-1,406) in the lisinopril and nisoldipine groups, respectively." | 5.09 | Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. ( Hansen, BV; Jensen, C; Parving, HH; Rossing, P; Tarnow, L, 2000) |
| "Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) versus an ACE inhibitor (lisinopril) on albuminuria, arterial blood pressure, and glomerular filtration rate (GFR) in hypertensive IDDM patients with diabetic nephropathy." | 5.08 | Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. ( Boelskifte, S; Jensen, BR; Nielsen, FS; Parving, HH; Rossing, P; Tarnow, L, 1997) |
| "Nisoldipine treatment for seven days is not associated with altered platelet function, but platelet hypersensitivity is observed after treatment for 24 hours in both insulin-dependent diabetics and controls." | 1.27 | Ex vivo platelet studies following oral nisoldipine in normotensive insulin-dependent diabetics and non-diabetic controls. ( Betteridge, DJ; Dandona, P; Hendra, TJ; Jeremy, JY; Oughton, J; Smith, CC; Yudkin, JS, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rossing, P | 4 |
| Tarnow, L | 4 |
| Boelskifte, S | 1 |
| Jensen, BR | 1 |
| Nielsen, FS | 2 |
| Parving, HH | 3 |
| Sørensen, VB | 1 |
| Parving, H | 1 |
| Nørgaard, T | 1 |
| Kastrup, J | 1 |
| Sato, A | 1 |
| Ali, S | 1 |
| Cooper, ME | 1 |
| Jensen, C | 1 |
| Hansen, BV | 1 |
| Hendra, TJ | 1 |
| Oughton, J | 1 |
| Jeremy, JY | 1 |
| Smith, CC | 1 |
| Betteridge, DJ | 1 |
| Dandona, P | 1 |
| Yudkin, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00311870] | Phase 4 | 52 participants | Interventional | 1993-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for nisoldipine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressur | 1997 |
Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Delayed-A | 1998 |
Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Ambulato | 1999 |
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressur | 2000 |
2 other studies available for nisoldipine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy: response to Tarnow et al.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabete | 2000 |
Ex vivo platelet studies following oral nisoldipine in normotensive insulin-dependent diabetics and non-diabetic controls.
Topics: Adenosine Diphosphate; beta-Thromboglobulin; Blood Platelets; Catecholamines; Collagen; Diabetes Mel | 1988 |